China MedTech – Navigating the Road Ahead

By: McKinsey & Company

Following the 2025 BioCentury & BayHelix China Healthcare Summit, McKinsey & Company expands the discussion with an in-depth analysis of how China’s healthcare landscape is evolving across biopharma and medtech. Drawing on the firm’s annual research and market observations, the whitepaper highlights the forces reshaping innovation, commercialization, and global collaboration.

Topics Discussed in White Paper:

• Balancing best-in-class and first-in-class innovation: How China’s biopharma sector is redefining competitive leadership.
• Evolving commercial and market access models: New frameworks emerging amid pricing reforms and shifting payer priorities.
• Cross-border investment and licensing: The next wave of partnerships bridging Chinese and global life sciences markets.
• Pathways for sustainable growth: How biotech and MedTech players can scale responsibly for long-term success.

With China’s role in global healthcare expanding, these insights provide essential guidance for biopharma and MedTech executives navigating a complex and fast-moving ecosystem.

Download the Whitepaper